A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib

Cancer type: Multiple diagnosis

Phase: II

Principal Investigator: Brunsvig Paal

Country: NO

Keywords: Norway, Oslo, BRAF V600E mutated, Rare Cancers, Dabrafenib, Trametinib

Status: Inclusion completed

Link to